Divalproex sodium reduces overall aggression in youth at high risk for bipolar disorder.
J Child Adolesc Psychopharmacol
; 16(3): 252-9, 2006 Jun.
Article
em En
| MEDLINE
| ID: mdl-16768633
ABSTRACT
INTRODUCTION:
The psychopharmacology of aggression in youth is relatively unexplored, even though such maladaptive aggression manifests across many different diagnoses.METHODS:
This study was a 12-week, open-label trial with divalproex sodium (DVPX) in 24 bipolar offspring 6-18 years of age (mean age = 11.3 years; 17 boys) with mixed diagnoses of major depression, cyclothymia, attention-deficit/hyperactivity disorder (ADHD), and oppositional defiant disorder (ODD). The Overt Aggression Scale (OAS) was used to measure aggression in 4-week intervals. We measured serum gamma-butyric acid (GABA) and glutamate levels at baseline and week 12.RESULTS:
Seventy-one percent of evaluable subjects were considered responders to DVPX treatment by the OAS. There was a significant correlation between the Young Mania Rating Scale (YMRS) and OAS scores at week 0 (p = 0.036) and week 12 (p = 0.025). Serum DVPX level did not correlate with treatment response.CONCLUSIONS:
These youths who are at high risk for bipolar disorder experienced an overall decrease in aggressive behavior in response to DVPX. Age or gender did not predict a positive response to DVPX. This study is the first report of treatment efficacy of a mood stabilizer for aggression in youth at high risk for bipolar disorder.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Ácido Valproico
/
GABAérgicos
/
Antimaníacos
/
Agressão
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article